Professional Essentials · True Rheumatic Emergencies · Free · No registration
Rapidly progressive glomerulonephritis
Recognize the renal trajectory, stabilize complications and connect urgent biopsy with disease-specific treatment.
1. Recognize a trajectory, not a creatinine threshold
Rapidly progressive glomerulonephritis (RPGN) describes a rapidly deteriorating glomerular syndrome, often evolving over days to weeks. It requires urgent hospital and nephrology assessment because reversible inflammation can become permanent kidney damage. The first question is how kidney function and urine findings have changed, not whether creatinine exceeds an arbitrary number.
Retrieve dated results. A substantial rise from a low baseline can be important even if the current value remains inside the laboratory reference interval. Assess urine output, dysmorphic erythrocytes, red-cell casts and proteinuria. Dipstick blood alone is insufficient: nonglomerular bleeding and pigment can produce a positive result. A single specimen without casts does not exclude glomerulonephritis.
The final KDIGO AKI guideline defines acute kidney injury using creatinine change or reduced urine output. These are AKI criteria, not diagnostic criteria for RPGN. Do not force an unknown time interval into an AKI calculator, or use a calculated eGFR during rapidly changing creatinine as a precise measure of current filtration.
Renal-limited disease may lack rash, sinus symptoms or hemoptysis. Negative ANCA and normal complement do not exclude important glomerular disease.
Renal trajectory and incomplete presentations → Professional access required
2. Stabilize and investigate in parallel
Immediately assess potassium-related cardiac risk, acid–base status, pulmonary edema, blood pressure, mental state and measured urine output. Dangerous hyperkalemia, severe acidosis, refractory overload or uremic complications can require urgent kidney replacement therapy. Dialysis decisions depend on clinical threats and trends rather than creatinine alone. Check perfusion and obstruction alongside the glomerular assessment.
Obtain blood count and platelets, electrolytes, bicarbonate, albumin, urine microscopy and protein quantification. Send MPO/PR3-ANCA and anti-GBM antibodies together; add ANA, anti-dsDNA and complement when indicated. Renal ultrasound helps assess obstruction and anatomy. Review nephrotoxins, hydralazine, antithyroid drugs, minocycline, cocaine/levamisole, checkpoint inhibitors, anticoagulation and prior immunosuppression.
New respiratory symptoms or opacities require assessment for alveolar hemorrhage, infection and edema; absence of hemoptysis is not reassuring. Arrange pulmonary/critical-care input when oxygen needs increase. Collect essential serology before plasma exchange if immediately possible. Document treatment and sampling times so later negative tests can be interpreted correctly.
Urgent investigations and disposition → Professional access required
3. Distinguish causes and dangerous mimics
Kidney biopsy separates pauci-immune necrotizing injury, linear anti-GBM staining and immune-complex disease. Crescents describe severe glomerular injury; they do not name its cause. Activity, chronicity and the fraction of preserved glomeruli matter when estimating reversibility.
ANCA supports a compatible phenotype but cannot establish vasculitis by itself. Endocarditis-associated glomerulonephritis may be ANCA-positive and crescentic, as demonstrated in the Boils biopsy cohort. Fever, valve or device history, a murmur and embolic findings should prompt cultures and cardiac assessment. Infection-directed treatment and source control may be the essential intervention; immunosuppression is not a default response to every inflammatory-looking biopsy.
Consider lupus, IgA disease, cryoglobulinemia, monoclonal deposits and C3 glomerulopathy. Staphylococcal IgA-dominant infection-related GN can mimic IgA nephropathy; prioritize infection control. In lupus, TMA treatment follows its mechanism: TTP, antiphospholipid syndrome and complement-mediated disease require different pathways; anticoagulation is not universal. Active nephritis can coexist. New hypertension with AKI in systemic sclerosis raises renal-crisis concern and makes reflex high-dose glucocorticoids hazardous.
Glomerular causes and renal mimics → Professional access required
4. Move tissue diagnosis and treatment together
Arrange urgent biopsy with nephrology and pathology, including appropriate tissue handling for light microscopy, immunofluorescence and electron microscopy. Review blood pressure, platelets, coagulation, antithrombotic exposure and procedural feasibility. A biopsy request is incomplete until the receiving service, timing and safety plan are established.
For a rapidly deteriorating, clinically compatible small-vessel vasculitis presentation with positive MPO- or PR3-ANCA, KDIGO 2024 supports starting treatment without waiting for the biopsy or report. Continue to obtain tissue when feasible. Strong suspicion of anti-GBM disease similarly warrants immediate specialist-directed treatment before confirmation.
These are cause-specific decisions. They do not justify administering pulse steroids to every unexplained AKI. When attribution is uncertain, keep urgent testing, infection assessment and biopsy moving while managing organ-threatening complications. Diagnostic uncertainty increases the need for coordinated hospital care; it does not create a routine outpatient waiting period.
Biopsy and treatment timing → Professional access required
5. Choose the disease-specific pathway
Organ-threatening ANCA vasculitis requires glucocorticoids plus rituximab or cyclophosphamide, selected by kidney severity, relapse, infection risk, fertility and previous exposure. RAVE excluded creatinine >4 mg/dL, limiting evidence for rituximab alone in severe kidney failure. PEXIVAS supports reduced-dose oral glucocorticoids with fewer serious infections. A retrospective severe-AAV cohort found more progression/relapse-inclusive events during reduced dosing; this warrants reassessment during tapering, not routine abandonment of the regimen.
Anti-GBM treatment generally combines daily plasma exchange until antibodies are undetectable, cyclophosphamide and glucocorticoids. Dialysis dependence alone does not establish futility: the narrow KDIGO exception requires dialysis at presentation plus 100% crescents or >50% global glomerulosclerosis in an adequate biopsy, and no pulmonary hemorrhage. Lung bleeding changes the decision even when kidney recovery is unlikely.
For active proliferative lupus nephritis, use glucocorticoids and biopsy-guided combination therapy. EULAR 2025 includes mycophenolate/obinutuzumab among options, but REGENCY excluded RPGN, eGFR <30 mL/min/1.73 m² and dialysis/transplantation need: these results do not establish emergency rescue efficacy. A calcineurin inhibitor is not automatic in severe renal impairment. Individualize induction with nephrology/rheumatology; taper improving patients toward prednisone ≤5 mg/day by 4–6 months.
For rapidly progressive IgA nephropathy, KDIGO 2025 advises cyclophosphamide and systemic glucocorticoids using an ANCA-type approach. Crescents without a concomitant decline in kidney function do not establish this subtype.
Treatment branches and their conditions → Professional access required
6. Individualize exchange and measure recovery
Plasma exchange is not routine for every crescentic GN. In AAV, KDIGO advises considering it with dialysis dependence, rapidly increasing creatinine, creatinine >3.4 mg/dL, or hypoxemic alveolar hemorrhage. For hemorrhage, ACR/VF conditionally recommends against routine addition; EULAR also advises against routine use. Balance potential kidney benefit against infection/procedural harms. PEXIVAS found no overall death/ESKD benefit; anti-GBM remains a separate indication.
Follow urine output, blood pressure, potassium, acid–base status, creatinine and respiratory findings together. Persistent proteinuria or hematuria can reflect residual damage and should not automatically trigger more immunosuppression. Deterioration requires renewed assessment for active disease, infection, obstruction, drug toxicity and hemodynamic causes.
Prescribing includes renal dose adjustment, blood-count monitoring, infection prophylaxis, and hepatitis B/IgG assessment before rituximab.
Avacopan update, October 4, 2026: ADVOCATE was retracted June 29. EU authorisation was revoked August 4. The UK stopped new starts September 1, allowing six months to transition existing patients before planned revocation March 1, 2027. US withdrawal remains proposed; treatment remains available during the regulatory process. Review alternatives and current local liver-safety instructions with patients. Older guideline recommendations require reassessment; avacopan is not routine rescue therapy here.
Handoff: dated creatinine, urine findings/output, oxygen support, blood pressure, potassium/acid–base threats, pre-treatment samples, biopsy plan, treatment given and ownership of pending results. Discuss transfer when biopsy/apheresis is unavailable. A creatinine plateau does not establish recovery.
After stabilization, define induction completion and maintenance, dialysis reassessment when relevant, and ownership of pending results. Double-positive ANCA/anti-GBM disease requires attention to later ANCA-type relapse risk. Provide explicit instructions for new breathlessness, fever, falling urine output or recurrent visible bleeding.
Monitoring and post-acute care → Professional access required
Selected sources
- KDIGO ANCA-associated vasculitis guideline,2024.
- KDIGO glomerular diseases guideline, 2021: anti-GBM chapter 11.
- KDIGO lupus nephritis guideline,2024.
- KDIGO IgAN/IgAV guideline,2025.
- KDIGO AKI guideline,2012.
- Walsh et al. PEXIVAS,2020.
- Boils et al. Endocarditis-associated GN,2015.
- EULAR lupus kidney involvement recommendations, 2025; FDA Gazyva label, REGENCY population (§14.3).
- ACR/VF AAV guideline, 2021; EULAR AAV update, 2022.
- Nagle et al., 2025: reduced-dose glucocorticoids in severe AAV (observational).
- Avacopan: NEJM retraction, June 29, 2026; EMA/EC final decision, August 4, 2026; MHRA, September 1, 2026; FDA withdrawal proposal, April 27, 2026; US prescribing information, May 2026.
Clinical review: October 4, 2026. This independent overview accompanies the full professional emergency module.